A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TQ-A3334 Tablet After Multiple Doses in Healthy Adult Subjects

This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects.

The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.

Study Overview

• Status: Completed
• Conditions: Hepatitis B
• Intervention / Treatment: Drug: TQ-A3334 tablets; Drug: TQ-A3334 placebo tablets

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130021
      • The First Hospital of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Sign the informed consent form before the study, and fully understand the study content, process and possible adverse events;
• Be able to complete the study according to the requirements of the protocol;
• Male and female subjects aged 18 to 55 years (inclusive);
• Male subjects weigh not less than 50 kg, female subjects weigh not less than 45 kg, Body Mass Index (BMI) in the range of 18 ~ 28 kg/m2 (inclusive);
• No clinically significant medical history of cardiac, hepatic, renal, gastrointestinal, neurological, respiratory, psychiatric abnormalities and metabolic abnormalities;
• Subjects (including partners) are willing to voluntarily take effective contraception within 2 weeks before screening to 6 months after the last dose of study drug.

Exclusion Criteria:

• Female subjects who are breastfeeding or plan to conceive or have a positive serum pregnancy results during the screening or study period;
• A pre-existing or current neuropsychiatric, respiratory, cardiovascular, gastrointestinal, hematologic-lymphatic, hepatic or renal insufficiency, endocrine, or musculoskeletal disease or other condition which, in the judgment of the Investigator, may have an effect on drug metabolism or safety;
• Eye diseases, including fundus lesions;
• History of clinically significant infections, including upper respiratory tract infections (URTI) and lower respiratory tract infections (LRTI), requiring antibiotic or antiviral medication within 14 days prior to screening or during screening;
• Acute illness or concomitant medication from the screening phase until study drug administration;
• History of dysphagia or any gastrointestinal disorder that interferes with drug absorption;
• Abnormal and clinically significant findings on vital signs, physical examination, laboratory tests, 12-lead electrocardiogram, abdominal ultrasound, and chest radiographs during the screening period;
• Positive for HBsAg in Hepatitis B, Hepatitis C, Syphilis, and Human Immunodeficiency Virus (HIV) antigen/antibody;
• Have taken any medication that can alter liver drug enzyme activity within 28 days prior to screening;
• Received immunoglobulin or blood product therapy within 30 days prior to screening;
• Have taken an investigational drug or participated in a clinical trial of any drug within 3 months prior to screening;
• Have taken Any prescription, over-the-counter, vitamin product, or herbal medication within 2 weeks prior to screening;
• Use of any systemic cytotoxic or systemic immunosuppressive drug within 6 months prior to screening or during the study period, or use of any localized cytotoxic or localized immunosuppressive drug within 30 days or 5 half-lives, whichever is longer, prior to screening or during the study period;
• Have undergone surgery within 4 weeks prior to screening or who plan to undergo surgery during the study period;
• Have lost blood or donated more than 400 mL of blood within 2 months prior to screening;
• Potential blood collection difficulties, history of needle and blood sickness;
• Having any clear history of drug or food allergy, especially to ingredients similar to those of the study drug;
• Those who smoked more than 5 cigarettes/day or used an equivalent amount of nicotine or nicotine-containing products within 3 months prior to screening, or who were unable to discontinue the use of any tobacco-based products during the trial;
• Those who have a history of chronic alcohol abuse or who have consumed more than 14 units of alcohol per week within 3 months prior to screening or who are unable to abstain from alcohol for the duration of the test or who have a positive breathalyzer test for alcohol;
• Those with a history of drug abuse or a positive urine drug screen;
• Those who can not avoid xanthine-rich beverages or foods or other factors that may affect drug absorption, distribution, metabolism, excretion, etc., from at least 1 day prior to study dosing until the end of the study;
• Subjects who, in the opinion of the investigator, have other factors that were unsuitable for participation in this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TQ-A3334 tablets (once a day); TQ-A3334 tablets, administered once a day.	Drug: TQ-A3334 tablets; TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
Placebo Comparator: TQ-A3334 placebo tablets (once a day); TQ-A3334 placebo tablets, administered once a day.	Drug: TQ-A3334 placebo tablets; TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Experimental: TQ-A3334 tablets (every other day); TQ-A3334 tablets, administered once every other day.	Drug: TQ-A3334 tablets; TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
Placebo Comparator: TQ-A3334 placebo tablets (every other day); TQ-A3334 placebo tablets, administered once every other day.	Drug: TQ-A3334 placebo tablets; TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Experimental: TQ-A3334 tablets (every three days); TQ-A3334 tablets, administered once every three days.	Drug: TQ-A3334 tablets; TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
Placebo Comparator: TQ-A3334 placebo tablets (every three days); TQ-A3334 placebo tablets, administered once every three days.	Drug: TQ-A3334 placebo tablets; TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of adverse events (AE)	Incidence of adverse events (AE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.	From patient enrollment to withdrawal, estimated to be around 1 month.
Severity of adverse events (AE)	Severity of adverse events (AE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.	From patient enrollment to withdrawal, estimated to be around 1 month.
Incidence of serious adverse events (SAE)	Incidence of serious adverse events (SAE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.	From patient enrollment to withdrawal, estimated to be around 1 month.
Severity of serious adverse events (SAE)	Severity of serious adverse events (SAE) evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.	From patient enrollment to withdrawal, estimated to be around 1 month.
Tolerability after drug administration	Tolerability is evaluated by the number of participants with abnormal laboratory examinations, vital signs, physical examination, electrocardiogram.	From patient enrollment to withdrawal, estimated to be around 1 month.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak Time (Tmax)	The time required to reach the highest concentration (peak drug concentration) on the human blood concentration curve after administration.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Peak concentration (Cmax)	The highest blood drug concentration achieved after administration.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration-area under time curve (AUC0-24)	The area under the plasma concentration-time curve from the beginning of the first administration to 24 hours.	From 60 minutes before administration on Day 1 to 24 hours after the last administration.
Plasma concentration-area under time curve (AUC0-24)	The area under the plasma concentration-time curve from the beginning of the first administration to the last measurable concentration point.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration-area under time curve (AUC0-∞)	Extrapolated from the first administration to the area under the plasma concentration-time curve to infinity.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Apparent volume of distribution (Vd/F)	The ratio of the drug dosage in the body to the blood drug concentration when the drug reaches dynamic equilibrium in the body.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Clearance (CL/F)	Ratio of drug clearance rate to administration concentration.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Elimination half-life time (t1/2)	The time it takes to reduce the concentration of drugs in the blood by half	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Time of maximum concentration under steady state (Tmax,ss)	Time required to reach steady-state peak concentration after administration.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Maximum concentration under steady state (Cmax, ss)	The highest blood drug concentration that occurs after reaching steady state.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Minimum concentration under steady state (Cmin, ss)	The lowest blood drug concentration that occurs after reaching steady state.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration at steady state (Cav, SS)	The plasma concentration at which the rate of administration and rate of elimination are in equilibrium.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Plasma concentration area under steady-state time curve (AUCss)	The area under the plasma concentration-time curve of the steady state.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Accumulation Index (Rac)	The ratio of steady-state blood drug concentration to blood drug concentration after the first administration.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Degree of fluctuation (DF)	The ratio of the difference between the maximum steady-state blood drug concentration and the minimum steady-state blood drug concentration to the average steady-state blood drug concentration.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-α concentration (IFN-α)	The change of subjects' blood IFN-α concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-stimulated gene concentration (ISG)	The change of subjects' blood ISG concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-gamma concentration (IFN-γ)	The change of subjects' blood IFN-γ concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Tumor Necrosis Factor-α concentration (TNF-α)	The change of subjects' blood TNF-α concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interleukin-6 concentration (IL-6)	The change of subjects' blood IL-6 concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interleukin-2 concentration (IL-2)	The change of subjects' blood IL-2 concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Monocyte Chemotactic Protein 1 concentration (MCP-1)	The change of subjects' blood MCP-1 concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
Interferon-inducible protein-10 concentration (IP-10)	The change of subjects' blood IP-10 concentration from baseline.	From 60 minutes before administration on Day 1 to 72 hours after the last administration.
QT/QT interval	Level of change in QT/QT interval to evaluate the drug cardiotoxicity.	From 30 minutes before administration on Day 1 to 48 hours after the last administration.

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): December 26, 2023
• Primary Completion (Actual): June 24, 2024
• Study Completion (Actual): August 19, 2024

Study Registration Dates

• First Submitted: November 30, 2023
• First Submitted That Met QC Criteria: November 30, 2023
• First Posted (Actual): December 7, 2023

Study Record Updates

• Last Update Posted (Actual): October 30, 2024
• Last Update Submitted That Met QC Criteria: October 28, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Blood-Borne Infections; Infections; Virus Diseases; Digestive System Diseases; Liver Diseases; Hepatitis, Viral, Human; Communicable Diseases; DNA Virus Infections; Hepadnaviridae Infections; Hepatitis; Hepatitis B
• Other Study ID Numbers: TQ-A3334-I-04

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No